Daiichi Sankyo doesn’t need help selling cancer drugs.

Enhertu alone is on track to clear $5 billion this year.

The DXd ADC platform that runs Enhertu is also behind Dato-DXd, HER3-DXd, I-DXd and a long list of other deruxtecan conjugates moving through late-stage trials.

So when Daiichi signs a research collaboration with a small, relatively unknown biotech, it’s worth asking what they think they’re getting.

That biotech is Interna Therapeutics, and the deal announced this week gives Daiichi access to Interna’s Molecular Nano Motor (MNM) platform, an intracellular delivery technology designed to actively transport therapeutic payloads inside cells.

“Active transport” is the key phrase.

Most delivery technologies in oncology, including ADC linker chemistry, lipid nanoparticles, and various conjugation systems, get the drug to the cell or even into the cell.

What happens after entry is largely passive.

The payload diffuses, gets trapped in endosomes, escapes (or doesn’t), reaches its target (or doesn’t).

The MNM platform is positioned as something different. It’s designed to keep moving once it’s inside the cell, actively shuttling payloads toward their intracellular targets. If it works, it could materially improve the functional activity of payloads that struggle with intracellular distribution.

The deal terms are sparse. No upfront, no milestones disclosed. That’s typical for early research collaborations. What matters is the signal value: Daiichi looking outside its own deep ADC and conjugation expertise to evaluate a platform from a small private biotech.

Daiichi has spent years building one of the most sophisticated ADC platforms in the industry. Their linker-payload combinations have set the bar for what targeted delivery can achieve. They have internal capabilities most companies would kill for.

And they’re still looking for ways to do delivery better. That tells you something about how hard the problem still is.

The intracellular delivery problem also extends well beyond ADCs. RNA therapies, particularly siRNA and ASOs, struggle with the same issue once they’re past the cell membrane. So do certain protein degraders and other small molecule modalities that need to reach specific subcellular compartments. A modality-agnostic delivery platform would have value across multiple therapeutic categories, which is exactly how Interna positions MNM.

For other angles on the targeted delivery and ADC evolution story, GlycoNex’s glycan-targeted ADC and CrossBridge Bio’s dual-payload approach are both worth a look. The space is moving fast.

The collaboration will reportedly assess MNM integration with Daiichi’s existing targeting strategies. Translation: they’re going to test whether bolting MNM onto deruxtecan-style payloads or other Daiichi platforms makes the conjugates work better.

If the answer is yes, expect a more substantial deal to follow. Daiichi has a track record of moving from research collaboration to acquisition or major licensing when the technology proves out. Just ask AstraZeneca, which paid $6 billion upfront in 2019 for the trastuzumab deruxtecan rights and another $6 billion for datopotamab deruxtecan.

For Interna, the validation alone is worth the deal. A research partnership with Daiichi puts them on the map of every other large pharma evaluating delivery technologies. If the data look good, they’ll have multiple suitors.

Watch this one. The financial terms are quiet, but the strategic signal is loud.